PHARMACOKINETICS OF LANSOPRAZOLE IN HEMODIALYSIS-PATIENTS

被引：5

作者：

KAROL, MD

MACHINIST, JM

CAVANAUGH, JM

机构：

[1] ABBOTT LABS,DEPT BIOTRANSFORMAT,ABBOTT PK,IL 60064

[2] ABBOTT LABS,DEPT CLIN PHARMACOL,ABBOTT PK,IL 60064

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1995年 / 35卷 / 08期

关键词：

D O I：

10.1002/j.1552-4604.1995.tb04125.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmacokinetics of the new benzimidazole proton pump inhibitor lansoprazole and five of its metabolites were assessed after single oral dose administration to five hemodialysis patients. Patients were studied on dialysis and nondialysis days. !Multiple blood and dialysate samples were collected after dosing and were assayed for lansoprazole and metabolite content via high-performance liquid chromatography. The degree of lansoprazole plasma protein binding was lower in hemodialysis patients than in subjects with normal renal function or patients with renal impairment not requiring dialytic therapy, although this tended to moderate when assessed immediately after dialysis. Examination of venous plasma concentration, paired arterial-venous concentration, and dialysate data revealed that lansoprazole and its metabolites were poorly dialyzable. No dosage adjustment of lansoprazole is necessary in hemodialysis patients nor is supplementation after hemodialysis sessions necessary.

引用

页码：815 / 820

页数：6

共 13 条

[1]

Barradell LB, Faulds D, McTavish D, Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid‐related disorders, Drugs, 44, pp. 225-250, (1992)

[2]

Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Menoit M, Flouvat B, The effect of food and antacids on lansoprazole absorption and disposition, Eur J Drug Metab Pharmacokinet, pp. 315-320, (1991)

[3]

Matano Y, Takemoto T, Miwa T, Iwasaki A, Asaoka A, Clinical study of the inhibitory effect of AG‐1749, a proton pump inhibitor, on nocturnal gastric acid secretion: evaluation of dosage and administration stage, Yakuri to Chiryo, 18, pp. 4865-4876, (1990)

[4]

Mitani M, Tsukamoto T, Yoshida S, Kobayashi T, Metabolic fate of AG‐1749, a new proton pump inhibitor, in rats, mice, and dogs, Jap Pharmacol Ther, 18, pp. 3413-3435, (1990)

[5]

Nakagawa A, Ooka T, Kim H, Sato N, Kamada T, Nakamura N, Study of lansoprazole (AG‐1749), antiulcer agent, tablet form, Rinsho Iyaku, 7, pp. 33-50, (1991)

[6]

Tateno M, Nakamura N, Phase I study of lansoprazole (AG‐1749), antiulcer agent, capsule form, Rinsho Iyaku, 7, pp. 51-62, (1991)

[7]

Karol MD, Machinist JM, Cavanaugh JH

[8]

Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M, Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity, European Journal of Clinical Pharmacology, 45, pp. 367-371, (1993)

[9]

Karol MD, Granneman GR, Alexander K, Determination of lansoprazole and five metabolites in plasma by high‐performance liquid chromatography, J Chromatogr B

[10]

Gibaldi M, Perrier D, Pharmacokinetics., (1982)

← 1 2 →